Promega Corporation’s bioluminescent assays are designed for the measurement of the relative activities of histone deacetylases
(HDACs) for basic research, screening, and drug discovery.
The HDAC-Glo and SIRT-Glo assays and screening systems use a
single-reagent-addition, add-mix-measure protocol for benchtop to
high-throughput screening applications. The HDAC-Glo assay is useful for
class I and II HDAC enzymes in cells, cell extracts, or purified enzyme; the
SIRT-Glo assay is useful for NAD+-dependent class III HDAC purified enzymes
(Sirtuins or SIRTs). The assays use the company’s patented Ultra-Glo
recombinant firefly luciferase technology in an add-mix-measure format where
the amount of light produced correlates to HDAC enzyme activity.
Promega is a leader in providing innovative solutions and technical support to the life sciences industry. Promega Corporation’s 2,000 products enable scientists worldwide to advance their knowledge in life science research, particularly in genomics, proteomics, and cellular analysis. Our products are also used to support molecular diagnostics and human identification. Founded in 1978, Promega Corporation is headquartered in Madison, Wisconsin, USA, with branches in twelve countries and over 50 global distributors.